Komori
Earnings4521KAKEN PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 (Japanese GAAP, Consolidated)

In the first quarter of the fiscal year ending March 2027, revenue increased 59.8% year on year, while operating income improved significantly from ¥14 million to ¥10,902 million. The full-year earnings forecast and annual dividend forecast remain unchanged.

Worth reading
36Immaterial
Scored from 3 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
59.8
Year-on-year change in revenue (%)
Wording
Conditional
How definitive the wording is.

Results for this period

First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAP
Net Sales30,154¥ millionYear on year +59.8%Progress 33.5%
Operating profit10,902¥ millionProgress 138.0%
Ordinary income11,258¥ millionProgress 130.9%
Net income attributable to owners of the parent8,439¥ millionProgress 129.8%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥222.86
Financial position at period-end
Total assets187,414¥ million
of which net assets 152,883 ¥ millionEquity ratio 81.6%vs. prior year-end -1.2pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥89,900 million (YoY +17.0%)
Operating profit¥7,900 million
Ordinary income¥8,600 million
Net income¥6,500 million (YoY +203.1%)
Annual Dividend Forecast¥190 → ¥190(0.0%)
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Not disclosed / Excluded Not disclosed / Material changes No
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End44,139,730 Shares
Treasury Shares at Period-End6,271,571 Shares
Results for this period
ItemDetails
Fiscal Period ClassificationFirst quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 April 2026 to 30 June 2026
Net Sales¥30,154 million (YoY +59.8%)
Operating profit¥10,902 million
Ordinary income¥11,258 million
Profit attributable to owners of the parent¥8,439 million
Net income per share¥222.86
Equity ratioEnd of the current fiscal period 81.6 / End of previous period 82.8
Total assets¥187,414 million
Net assets¥152,883 million
Full-year earnings forecastNet Sales ¥89,900 million (YoY +17.0%) / Operating profit ¥7,900 million / Ordinary income ¥8,600 million / Net income ¥6,500 million (YoY +203.1%)
Annual Dividend Forecast¥190 → ¥190(0.0%)
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew Not disclosed / Excluded Not disclosed / Material changes No
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End44,139,730 Shares
Treasury Shares at Period-End6,271,571 Shares
Items this document does not state (18)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossBreakdown of extraordinary income (loss)Disclosure regarding the going concern assumptionMaterial subsequent eventsFactors Behind Changes in Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Not disclosed

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 (Japanese GAAP, Consolidated) | KAKEN PHARMACEUTICAL CO.,LTD. (4521) timely disclosure | Komori